Effects of Sacubitril/Valsartan on left ventricular pressure-volume relationship in heart failure

Autor: T Stegmann, L Parentin, S H Schirmer, A Hagendorff, U Laufs, D Lavall

Publikováno v: European Heart Journal. 43

Background In patients with heart failure (HF) and reduced ejection fraction, Sacubitril/Valsartan (S/V) reduces the risk for death and hospitalisations. However, the underlying mechanism for these beneficial effects of S/V, is still lacking. Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f133716601e90711d1d6cb1a5359c98a
https://doi.org/10.1093/eurheartj/ehac544.155

[Heart rate: clinical variable and risk marker]

Autor: F, Custodis, J-C, Reil, S H, Schirmer, O, Adam, S, Möhlenkamp, U, Laufs, M, Böhm

Publikováno v: Deutsche medizinische Wochenschrift (1946). 139(33)

Heart rate is an easily accessible clinical variable with wide-ranging prognostic impact. Elevated resting heart rate predicts an elevated cardiovascular risk. Epidemiological studies demonstrate a relevant association between heart rate and survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::39b51efd7f253d4fee8e4f92154d28e5
https://pubmed.ncbi.nlm.nih.gov/25093954

[Update on anti-platelet therapy]

Autor: S H, Schirmer, M, Böhm

Publikováno v: Deutsche medizinische Wochenschrift (1946). 136(23)

Use of the ADP (P2Y(12))-receptor antagonist clopidogrel is a cornerstone of dual platelet inhibition in acute coronary syndromes and following stent implantation. Because of the metabolization into its active form and the irreversible inhibition of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::090741f4a09a3bd7e09b4f89d6026c65
https://pubmed.ncbi.nlm.nih.gov/21630174

[Mechanisms and potential of the therapeutic stimulation of arteriogenesis]

Autor: S H, Schirmer, N, van Royen, U, Laufs, M, Böhm

Publikováno v: Deutsche medizinische Wochenschrift (1946). 134(7)

The stimulation of collateral artery growth (arteriogenesis) is a promising alternative approach to non-invasively treat arterial obstructive disease, such as coronary, peripheral or cerebral artery disease. Patients unable to undergo conventional re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::12b8f3c33be6b2e406cd395c569922c6
https://pubmed.ncbi.nlm.nih.gov/19197812

Outcomes of Left Main Chronic Total Occlusion Percutaneous Coronary Interventions.

Autor: Strepkos D; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Alexandrou M; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Mutlu D; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Carvalho PEP; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Choi JW; Department of Cardiology, Texas Health Presbyterian Hospital, Dallas, Texas, USA., Gorgulu S; Department of Cardiology, Biruni University Medical School, Istanbul, Turkey., Jaffer FA; Department of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA., Chandwaney R; Department of Cardiology, Oklahoma Heart Institute, Tulsa, Oklahoma, USA., Alaswad K; Department of Cardiology, Henry Ford Cardiovascular Division, Detroit, Michigan, USA., Basir MB; Department of Cardiology, Henry Ford Cardiovascular Division, Detroit, Michigan, USA., Azzalini L; Department of Cardiology, University of Washington Medical Center, Seattle, Washington, USA., Mastrodemos OC; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Rangan BV; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Voudris K; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Jalli S; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Burke MN; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Sandoval Y; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA., Brilakis ES; Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Publikováno v: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.